Kepler Capital Markets set a GBX 6,470 ($84.54) price target on AstraZeneca (LON:AZN) in a report published on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts also recently commented on AZN. Goldman Sachs Group set a GBX 5,000 ($65.33) target price on AstraZeneca and gave the company a sell rating in a research note on Monday. UBS Group reiterated a sell rating and set a GBX 5,400 ($70.56) target price on shares of AstraZeneca in a research note on Tuesday, May 7th. Deutsche Bank reiterated a buy rating and set a GBX 6,800 ($88.85) target price (down from GBX 6,900 ($90.16)) on shares of AstraZeneca in a research note on Friday, May 10th. Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a research note on Friday, March 29th. Finally, Jefferies Financial Group reiterated a hold rating and set a GBX 6,400 ($83.63) target price on shares of AstraZeneca in a research note on Friday, March 29th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of GBX 6,397.70 ($83.60).
AstraZeneca stock opened at GBX 5,813.98 ($75.97) on Monday. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. AstraZeneca has a twelve month low of GBX 5,110 ($66.77) and a twelve month high of GBX 6,540 ($85.46). The company has a market capitalization of $76.36 billion and a P/E ratio of 30.60.
In other news, insider Marc Dunoyer purchased 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The shares were purchased at an average cost of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley purchased 520 shares of the stock in a transaction dated Tuesday, April 30th. The shares were purchased at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.